

Salinomycin Suppresses PDGFR β , MYC, and Notch Signaling in Human Medulloblastoma

Shuang Zhou

Department of Pediatric Surgery, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China

Corresponding Author:

Shuang Zhou,
Department of Pediatric Surgery, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China

Received Date : Sep 12, 2023

Accepted Date : Sep 15, 2023

Published Date : Oct 16, 2023

Abstract

The most frequent brain tumour in children is medulloblastoma (MB). Despite better treatment and care, over 30% of people pass away from the illness. The effects of salinomycin on cell proliferation, cell death, and cell cycle progression in human MB cell lines were examined in an effort to find a more potent therapy approach. The findings showed that salinomycin interrupts cell cycle progression, promotes cell death, and reduces cell proliferation in MB cells. Salinomycin's effects on the expression of crucial genes involved in proliferation and survival signalling were also examined, and it was discovered that salinomycin up-regulates the expression of cyclin A while down-regulating the expression of PDGFR, MYC, p21, and Bcl-2. The outcomes also show that salinomycin inhibits Hes1 and Hes5 expression in MB cells. Our findings give light on salinomycin's potential as a novel therapeutic treatment for MB patients.

Abbreviations

PDGFR stands for beta-type platelet-derived growth factor receptor; Bcl-2 stands for B-cell lymphoma 2; DLL1 stands for delta-like 1 in drosophila; DLL3 stands for delta-like 3 in drosophila; Hes1 stands for hairy and enhancer of split 1 in drosophila; Hey1 stands for hairy and enhancer of split related with yrpw motif 1; Hey2 stands for hairy and enhancer MAML1 stands for Mastermind-Like 1 (Drosophila), MAML2 for Mastermind-Like 2, and MAML3 for Mastermind-Like 3 (Drosophila). RBPJ stands for Recombination Signal Binding Protein for Immunoglobulin Kappa J Region (4-Sulfophenyl) Dimethyl sulfoxide; -2H- Tetrazolium, Inner Salt MAML1 stands for Mastermind-Like 1, MAML2 for Mastermind-Like 2, and MAML3 for Mastermind-Like 3. Immunoglobulin Kappa J Region Recombination Signal Binding Protein; MTS: 3-(4, 5-Dimethylthiazol-2-Yl)-5-(3-Carboxymethoxyphenyl)-2- (4-Sulfophenyl) Dimethyl sulfoxide; -2H- Tetrazolium, Inner Salt

Introduction

The most typical malignant brain tumour in children is called a medulloblastoma (MB), an embryonal neuroepithelial tumour of the cerebellum [1]. Early on in its progression, this highly invasive tumour has a propensity to spread throughout the central nervous system. Around one-third of patients with MB tumours are still incurable, despite improvements in medical treatment outcomes for children with MB over the past few decades. Moreover, existing medical procedures have side effects that are hazardous and can leave long-term survivors with serious problems [2]. As a result, more potent medications are required to treat MB sufferers. Salinomycin, a mono carboxylic polyether antibiotic with a molecular weight of 751, is a common anti-coccidial medication. In comparison to paclitaxel, a commonly prescribed medication for breast cancer, salinomycin has recently been demonstrated to significantly lower the fraction of breast cancer stem cells (CSC) [3]. Salinomycin is a selective killer of human CSC and an effective murderer of multi-drug resistant human CSC-like cells, according to cumulative data [4-11]. Salinomycin has been demonstrated to regulate a number of signalling pathways, including the Wnt, NF-B, and p38 MAPK pathways, in cancer and CSCs [12-14]. MB cells are thought to have stem cell origins because of their capacity to develop into neuronal and/or glial cells [15,16]. A CSC-like population may exist and

contribute to MB treatment resistance, according to mounting data [17–19]. Through controlling downstream effectors such as MYC, Notch signalling is essential for cell differentiation and proliferation and is vital for the onset and progression of MB [20–22]. The Notch pathway inhibitors, such as the -secretase inhibitor MK-0752, suppress the cleavage of Notch, eradicate the stem cell-like population [23–25], reduce cell proliferation, and increase apoptosis [23–25], which implicates Notch signalling as a target and may represent a further promising treatment approach for MB patients. In the current investigation, we for the first time identified salinomycin's anticancer properties in cell lines of 3 MB. Also, we examined how salinomycin affected the expression of a few genes essential for MB cell proliferation, survival, and differentiation.

Discussion

In this investigation, we discovered that salinomycin strongly suppresses cell proliferation at concentrations between 0.25 and 4 M and causes cell death and cell cycle arrest. Salinomycin suppresses the expression of PDGFR, MYC, Bcl-2, p21 and some important effectors in the Notch signalling pathway, according to our analysis of changes in gene and/or protein expression that are involved in cell proliferation, cell death, and the Notch signalling pathway in response to salinomycin treatment (e.g., Hes1). Salinomycin has been demonstrated to have potent anti-cancer and anti-CSC actions in additional cancer types in vitro, in vivo xenografted mouse models, as well as pilot clinical investigations in people [33–35] after the revelation that salinomycin has anti-CSC activity in breast cancer [3]. Despite this, the Salinomycin's effects on MB cells haven't been investigated before. In this study, we show that salinomycin exerts severe cytotoxicity towards human MB cells. A dose-dependent increase in cell mortality (the sub-G0 population) and a notable decrease in cell proliferation after salinomycin therapy provided evidence for this finding. Cyclin A is necessary for DNA replication in both the S and G2 phases [36]. As salinomycin therapy prolongs the S and G2 phases, higher amounts of cyclin A may be the result. Also, there was a strong correlation between the data on cell proliferation and the cell cycle arrest during S-G2 phases and up-regulation of cyclin A expression. Hes1 and Hes5 are essential Notch signalling pathway effectors that are necessary for the development of MB illness and patient survival. Hes1 expression that is activated by Notch signalling is linked to considerably worse survival in MB patients, according to a study by Fan et al. [24]. The blocking of the Notch pathway has also been linked to cell death, cell cycle

exit, and differentiation in MB cells, according to research by the same team [23]. According to this study, Notch signalling may be important for maintaining MB CSCs.

Our findings demonstrate that salinomycin reduced the transcription of Hes1 and DLL1. This showed its significance in the preservation of MB CSCs and partially explained the effects of salinomycin on MB cell survival. Moreover, MAML1, which was likewise reduced by salinomycin in MB cells, which had previously been demonstrated to serve as a coactivator to increase the Notch-induced transcription of Hes1 [37]. The downregulated protein levels of p21, another target gene of Notch signalling, may also be partially explained by the inhibition of the Notch signalling gene expression [38]. The downstream target of canonical Wnt signalling has been identified as MYC [39]. In fact, in Wnt-transfected HEK293 cells, salinomycin inhibits the phosphorylation of the Wnt co-receptor lipoprotein receptor related protein 6 (LRP6) and causes its destruction [13]. It's likely that salinomycin's effect on Wnt signalling contributed to the downregulation of MYC. Salinomycin has been shown in this study to decrease Notch signalling in MB cells, and MYC is another target molecule for Notch signalling [40,41]. There's a chance that salinomycin uses Notch signalling to at least partially downregulate MYC. Furthermore, PDGFR signalling is downstream of MYC [42,43]. As a result, simultaneously addressing these routes for MB should offer an efficient treatment plan. MYC is frequently dysregulated in MB [44–46] and affects a variety of cellular processes by changing the expression of several functionally significant target genes [47]. According to recent research, of the four subtypes of MB, Group 3 MB, which is characterised by MYC overexpression, is associated with an aggressive illness and a poor prognosis [48]. Moreover, inhibiting MYC dramatically slows the development of MB cells [49]. High levels of PDGFR have also been linked to an aggressive phenotype of MB, in addition to MYC [50]. Our findings in this study reveal a novel molecular element of salinomycin's significant anti-cancer activities and emphasise the usefulness of salinomycin as a very promising therapy for treating MB by demonstrating that salinomycin may reduce the expression of MYC and PDGFR simultaneously [51].

Conclusions

Our research shows that salinomycin causes cytotoxicity in human MB cells. Our findings show that salinomycin therapy is effective in preventing MB cell proliferation, delaying the cell cycle, and triggering cell death. We further demonstrate that salinomycin therapy has changed several signalling pathways

in MB cells. The cytotoxic effects of salinomycin are most likely a result of the down-regulation of PDGFR and MYC as well as the inhibition of the Notch signalling pathway. When taken as a whole, this study implies that salinomycin may be a useful therapeutical drug for MB and calls for additional research.

REFERENCES

- Gilbertson RJ, Ellison DW. The origins of medulloblastoma subtypes. *Annu Rev Pathol*. 2008; 3: 341-365.
- Hadjipanayis CG, Van Meir EG. Brain cancer propagating cells: biology, genetics and targeted therapies. *Trends Mol Med*. 2009; 15: 519-530.
- Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. *Cell*. 2009; 138: 645-659.
- Chapkin RS, Kim W, Lupton JR, McMurray DN. Dietary docosahexaenoic and eicosapentaenoic acid: emerging mediators of inflammation. *Prostaglandins Leukot Essent Fatty Acids*. 2009; 81: 187-191.
- Fuchs D, Daniel V, Sadeghi M, Opelz G, Naujokat C. Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells. *Biochem Biophys Res Commun*. 2010; 394: 1098-1104.
- Fuchs D, Heinold A, Opelz G, Daniel V, Naujokat C. Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells. *Biochem Biophys Res Commun*. 2009; 390: 743-749.
- Kim JH, Chae M, Kim WK, Kim YJ, Kang HS, Kim HS, et al. Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein. *Br J Pharmacol*. 2011; 162: 773-784.
- Kim JH, Yoo HI, Kang HS, Ro J, Yoon S. Salinomycin sensitizes antimitotic drugs-treated cancer cells by increasing apoptosis via the prevention of G2 arrest. *Biochem Biophys Res Commun*. 2012; 418: 98-103.
- Kim KY, Yu SN, Lee SY, Chun SS, Choi YL, Park YM, et al. Salinomycin-induced apoptosis of human prostate cancer cells due to accumulated reactive oxygen species and mitochondrial membrane depolarization. *Biochem Biophys Res Commun*. 2011b; 413: 80-86.
- Kim WK, Kim JH, Yoon K, Kim S, Ro J, Kang HS, et al. Salinomycin, a glycoprotein inhibitor, sensitizes radiation-treated cancer cells by increasing DNA damage and inducing G2 arrest. *Invest New Drugs*. 2012; 30: 1311-1318.
- Zhou S, Wang F, Wong ET, Fonkem E, Hsieh TC, Wu JM, et al. Salinomycin: a novel anti-cancer agent with known anti-coccidial activities. *Curr Med Chem*. 2013; 20: 4095-4101.
- Ketola K, Hilvo M, Hyötyläinen T, Vuoristo A, Ruskeepää AL, Oreic M, et al. Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress. *Br J Cancer*. 2012; 106: 99-106.
- Lu D, Choi MY, Yu J, Castro JE, Kipps TJ, Carson DA. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. *Proc Natl Acad Sci U S A*. 2011; 108: 13253-13257.
- Zhang B, Wang X, Cai F, Chen W, Loesch U, Bitzer J, et al. Effects of salinomycin on human ovarian cancer cell line OV2008 are associated with modulating p38 MAPK. *Tumour Biol*. 2012; 33: 1855-1862.
- Keles GE, Berger MS, Lim R, Zaheer A, et al. Expression of glial fibrillary acidic protein in human medulloblastoma cells treated with recombinant glia maturation factor-beta. *Oncol Res*. 1992; 4: 431-437.
- Burger PC, Grahmann FC, Blietle A, Kleihues P. Differentiation in the medulloblastoma. A histological and immunohistochemical study. *Acta Neuropathol*. 1987; 73: 115-123.
- Morrison LC, McClelland R, Aiken C, Bridges M, Liang L, Wang X, et al. Deconstruction of medulloblastoma cellular heterogeneity reveals differences between the most highly invasive and self-renewing phenotypes. *Neoplasia*. 2013; 15: 384-398.
- Tang X, Yao Y, Zhu J, Jin K, Wang Y, Mao Y, et al. Differential

- proliferative index of cancer stem-like cells in primary and recurrent medulloblastoma in human. *Childs Nerv Syst.* 2012; 28: 1869-1877.
19. Zanini C, Ercole E, Mandili G, Salaroli R, Poli A, Renna C, et al. Medullospheres from DAOY, UW228 and ONS-76 cells: increased stem cell population and proteomic modifications. *PLoS One.* 2013; 8: e63748.
20. Bernard F, Krejci A, Housden B, Adryan B, Bray SJ. Specificity of Notch pathway activation: twist controls the transcriptional output in adult muscle progenitors. *Development.* 2010; 137: 2633-2642.
21. Manoranjan B, Venugopal C, McFarlane N, Doble BW, Dunn SE, Scheinemann K, et al. Medulloblastoma stem cells: where development and cancer cross pathways. *Pediatr Res.* 2012; 71: 516-522.
22. Palomero T, Ferrando A. Oncogenic NOTCH1 control of MYC and PI3K: challenges and opportunities for anti-NOTCH1 therapy in T-cell acute lymphoblastic leukemias and lymphomas. *Clin Cancer Res.* 2008; 14: 5314- 5317.
23. Fan X, Matsui W, Khaki L, Stearns D, Chun J, Li YM, et al. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. *Cancer Res.* 2006; 66: 7445-7452.
24. Fan X, Mikolaenko I, Elhassan I, Ni X, Wang Y, Ball D, et al. Notch1 and notch2 have opposite effects on embryonal brain tumor growth. *Cancer Res.* 2004; 64: 7787-7793.
25. Hallahan AR, Pritchard JI, Hansen S, Benson M, Stoeck J, Hatton BA, et al. The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. *Cancer Res.* 2004; 64: 7794-7800.
26. He XM, Wikstrand CJ, Friedman HS, Bigner SH, Pleasure S, Trojanowski JQ, et al. Differentiation characteristics of newly established medulloblastoma cell lines (D384 Med, D425 Med, and D458 Med) and their transplantable xenografts. *Lab Invest.* 1991; 64: 833-843.
27. Abouantoun TJ, Castellino RC, MacDonald TJ. Sunitinib induces PTEN expression and inhibits PDGFR signaling and migration of medulloblastoma cells. *J Neurooncol.* 2010; 101: 215-226.
28. Abouantoun TJ, Macdonald TJ. Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet- derived growth factor receptor and transactivation of epidermal growth factor receptor. *Mol Cancer Ther.* 2009; 8: 1137-1147.
29. Park AK, Lee SJ, Phi JH, Wang KC, Kim DG, Cho BK, et al. Prognostic classification of pediatric medulloblastoma based on chromosome 17p loss, expression of MYCC and MYCN, and Wnt pathway activation. *Neuro Oncol.* 2012; 14: 203-214.
30. Stearns D, Chaudhry A, Abel TW, Burger PC, Dang CV, Eberhart CG. c-myc overexpression causes anaplasia in medulloblastoma. *Cancer Res.* 2006; 66: 673-681.
31. Borggrefe T, Oswald F. The Notch signaling pathway: transcriptional regulation at Notch target genes. *Cell Mol Life Sci.* 2009; 66: 1631-1646.
32. Zweidler-McKay PA. Notch signaling in pediatric malignancies. *Curr Oncol Rep.* 2008; 10: 459-468.
33. Huczynski A. Salinomycin: a new cancer drug candidate. *Chem Biol Drug Des.* 2012; 79: 235-238.
34. Naujokat C, Fuchs D, Opelz G. Salinomycin in cancer: A new mission for an old agent. *Mol Med Rep.* 2010; 3: 555-559.
35. Naujokat C, Steinhart R. Salinomycin as a drug for targeting human cancer stem cells. *J Biomed Biotechnol.* 2012; 2012: 950658.
36. Pagano M, Pepperkok R, Verde F, Ansorge W, Draetta G. Cyclin A is required at two points in the human cell cycle. *EMBO J.* 1992; 11: 961-971. Wu L, Aster JC, Blacklow SC, Lake R, Artavanis-Tsakonas S, Griffin JD. MAML1, a human homologue of Drosophila mastermind, is a transcriptional co-activator for NOTCH receptors. *Nat Genet.* 2000; 26: 484-489.
37. Wu L, Aster JC, Blacklow SC, Lake R, Artavanis-Tsakonas S, Griffin JD. MAML1, a human homologue of Drosophila mastermind, is a transcriptional co-activator for NOTCH

- p receptors.
- Nat Genet.*
- 2000; 26: 484-489.
38. Rangarajan A, Talora C, Okuyama R, Nicolas M, Mammucari C, Oh H, et al. Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. *EMBO J.* 2001; 20: 3427-3436.
 - Yochum GS, Cleland R, Goodman RH. A genome-wide screen for beta- catenin binding sites identifies a downstream enhancer element that controls c-Myc gene expression. *Mol Cell Biol.* 2008; 28: 7368-7379.
 39. Yochum GS, Cleland R, Goodman RH. A genome-wide screen for beta- catenin binding sites identifies a downstream enhancer element that controls c-Myc gene expression. *Mol Cell Biol.* 2008; 28: 7368-7379.
 40. Ntziachristos P, Lim JS, Sage J, Aifantis I. From Fly Wings to Targeted Cancer Therapies: A Centennial for Notch Signaling. *Cancer Cell.* 2014; 25: 318-334.
 41. Orian A, Delrow JJ, Rosales Nieves AE, Abed M, Metzger D, Paroush Z, et al. A Myc-Groucho complex integrates EGF and Notch signaling to regulate neural development. *Proc Natl Acad Sci USA.* 2007; 104: 15771-15776.
 42. Romashkova JA, Makarov SS. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. *Nature.* 1999; 401: 86-90.
 43. Armelin HA, Armelin MC, Kelly K, Stewart T, Leder P, Cochran BH, et al. Functional role for c-myc in mitogenic response to platelet-derived growth factor. *Nature.* 1984; 310: 655-660.
 44. Bigner SH, Friedman HS, Vogelstein B, Oakes WJ, Bigner DD. Amplification of the c-myc gene in human medulloblastoma cell lines and xenografts. *Cancer Res.* 1990; 50: 2347-2350.
 45. Herms J, Neidt I, Lüscher B, Sommer A, Schürmann P, Schröder T, et al. C-MYC expression in medulloblastoma and its prognostic value. *Int J Cancer.* 2000; 89: 395-402.
 46. Siu IM, Lal A, Blankenship JR, Aldosari N, Riggins GJ. c-Myc promoter activation in medulloblastoma. *Cancer Res.* 2003; 63: 4773-4776.
 47. Cappellen D, Schlange T, Bauer M, Maurer F, Hynes NE. Novel c-MYC target genes mediate differential effects on cell proliferation and migration. *EMBO Rep.* 2007; 8: 70-76.
 48. Eberhart CG. Three down and one to go: modeling medulloblastoma subgroups. *Cancer Cell.* 2012; 21: 137-138.
 49. von Bueren AO, Shalaby T, Oehler-Jänne C, Arnold L, Stearns D, Eberhart CG, et al. RNA interference-mediated c-MYC inhibition prevents cell growth and decreases sensitivity to radio- and chemotherapy in childhood medulloblastoma cells. *BMC Cancer.* 2009; 9: 10.
 50. Gilbertson RJ, Clifford SC. PDGFRB is over expressed in metastatic medulloblastoma. *Nat Genet.* 2003; 35: 197-198.
 51. Wang Y. Effects of salinomycin on cancer stem cell in human lung adenocarcinoma A549 cells. *Med Chem.* 2011; 7: 106-111.